Endocrine-Related Cancer
@endocancer.bsky.social
Publishing translational & clinical investigations of human health & disease focusing on #endocrine neoplasias & hormone-dependent #cancers. Owned by Society of Endocrinology.
Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
November 13, 2025 at 12:54 PM
Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
November 11, 2025 at 12:20 PM
🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
November 10, 2025 at 12:49 PM
Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
November 5, 2025 at 8:18 AM
We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
Reposted by Endocrine-Related Cancer
🎉 Excited to share our new publication!
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
November 1, 2025 at 4:03 PM
🎉 Excited to share our new publication!
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
October 29, 2025 at 9:31 AM
Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
October 21, 2025 at 9:03 AM
🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Early-Career Editor Opening!
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
October 17, 2025 at 8:58 AM
Early-Career Editor Opening!
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
September 30, 2025 at 8:24 AM
New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
September 25, 2025 at 9:00 AM
New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
September 24, 2025 at 7:39 AM
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
Reposted by Endocrine-Related Cancer
Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer | OncLive
Neoadjuvant palbociclib plus endocrine therapy did not improved PEPI scores in operable hormone receptor–positive breast cancer.
www.onclive.com
September 17, 2025 at 12:35 PM
Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
Reposted by Endocrine-Related Cancer
Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more.
Explore the collection: erc.bioscientifica.com/page/PPGL
Explore the collection: erc.bioscientifica.com/page/PPGL
September 16, 2025 at 9:27 PM
Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more.
Explore the collection: erc.bioscientifica.com/page/PPGL
Explore the collection: erc.bioscientifica.com/page/PPGL
🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
September 16, 2025 at 9:53 AM
🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
September 9, 2025 at 1:44 PM
New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
September 5, 2025 at 3:07 PM
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
September 3, 2025 at 7:42 AM
🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
🌱Endocrine-Related Cancer is officially on LinkedIn!
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
August 29, 2025 at 10:31 AM
🌱Endocrine-Related Cancer is officially on LinkedIn!
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
✨ Systems biology approaches are reshaping our understanding of cancer.
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
August 26, 2025 at 8:11 AM
✨ Systems biology approaches are reshaping our understanding of cancer.
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at Griffith University, has joined Endocrine-Related Cancer's editorial board as an Associate Editor.
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
August 20, 2025 at 8:34 AM
🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at Griffith University, has joined Endocrine-Related Cancer's editorial board as an Associate Editor.
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
August 18, 2025 at 9:10 AM
Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy?
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
August 12, 2025 at 8:16 AM
🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy?
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
How do treatments for neuroendocrine neoplasms impact quality of life?
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
August 7, 2025 at 10:19 AM
How do treatments for neuroendocrine neoplasms impact quality of life?
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer!
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
July 29, 2025 at 10:20 AM
✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer!
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
Reposted by Endocrine-Related Cancer
The special collection in @endocancer.bsky.social - "From Discovery Science to the Clinic - Heritable Endocrine Cancers and Related Disorders" is open & calling for contributions. Edited by myself, Lois Mulligan & Joanne Ngeow in memory of Prof Charis Eng erc.bioscientifica.com/page/heritab... 🧪
July 22, 2025 at 2:33 PM
The special collection in @endocancer.bsky.social - "From Discovery Science to the Clinic - Heritable Endocrine Cancers and Related Disorders" is open & calling for contributions. Edited by myself, Lois Mulligan & Joanne Ngeow in memory of Prof Charis Eng erc.bioscientifica.com/page/heritab... 🧪